Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-06-07

Butterfly Network, Inc.

Butterfly Network sells handheld ultrasound probes, cloud imaging software, and AI-enabled workflow tools to clinicians, health systems, educators, and developers.

ai healthcare medical devices semiconductors software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

From handheld device to ultrasound control layer

The upside case rests on moving beyond probe sales into software, licensing, and distributed-care workflow capture. The product is real and shipping today, but the rerating depends on proving those added layers become repeatable rather than episodic.

Analysis

Thesis

Butterfly can roughly double equity value by 2031 if it converts a real handheld-ultrasound product lead into a higher-quality mix of enterprise workflow, embedded licensing, and distributed-care imaging, with AI reducing training friction and expanding where ultrasound can be used.

Last Economy Alignment

AI makes ultrasound easier to acquire, interpret, and deploy in lower-resource settings, and Butterfly owns a regulated probe-plus-workflow stack that can capture that demand. The score stops short of very high because larger imaging OEMs can still bundle hardware and software around it.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.5x (from 5 most recent analyses)

Reasoning

The upside does not require fantasy assumptions that Butterfly becomes the dominant imaging company. It mostly requires turning probe placements into stickier software, licensing, and governance revenue so the business quality improves. If that happens, the market can support a better growth multiple than a single-product device company, even with some maturation discount over time.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not whether Butterfly’s core technology works; it does. The real risk is whether the company can turn that hardware foothold into repeatable higher-margin layers before regulatory timing, supplier concentration, and larger imaging vendors slow or blunt the transition. If newer revenue streams stay lumpy or concentrated, the stock can grow into its value only slowly.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

No material new SEC filing or official IR announcement appeared in the last 7-10 days; the thesis still rests on the April 30, 2026 operating update.
As of June 7, 2026, Butterfly has not yet announced the first Home and Community Care commercial agreement that management had framed around mid-2026, so that gate remains open.
Near-term evidence still favors improving mix and credibility rather than a new fundamental step-up: Q1 2026 guidance was reaffirmed, but no fresh partner-clearance or home-care milestone has reset the story higher.

Forecast update

Upside now leans slightly more on revenue execution and mix quality than on pure multiple expansion because the stock has already rerated from prior lows while the next proof points are still pending.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.51

They own the handheld probe and enough of the clinical workflow that cheaper AI can make ultrasound useful in many more places, which can feed more software and partner revenue back into the installed base. The risk is that bigger imaging vendors bundle similar tools and Butterfly never becomes the trusted operating layer.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$5.69

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research